Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  raltitrexed
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to5
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0143, NCT00234429
Phase III Randomized Study of Raltitrexed Versus Standard Leucovorin Calcium-Modulated Bolus Fluorouracil for Stage III Colon Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: EORTC-40962, PETACC-1
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-08983, NCT00004920
Phase II Study of ICI D1694, a Thymidylate Synthase Inhibitor, for Advanced Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-6293, E6293
Phase II Study of ICI D1694 for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 06/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9519
Phase II Study of ICI D1694 (a Thymidylate Synthase Inhibitor) for Advanced Hormone-Refractory Prostate Cancer (Summary Last Modified 08/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCCTG-935251, NCCTG-93-52-51
Phase II Study of Raltitrexed (Tomudex) in Adult Recurrent Metastatic Soft Tissue Sarcomas (Summary Last Modified 03/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 15-75
Sponsor: Pharmaceutical / Industry
Protocol IDs: EORTC-62951
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-08992, NCT00004254
Phase II Study of ICI D1694, a Thymidylate Synthase Inhibitor, in Patients with Pancreatic or Gastric Adenocarcinoma (Summary Last Modified 07/93)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-93019, NCI-V93-0246
Phase II Study of ICI D1694 (a Thymidylate Synthase Inhibitor) in Patients with Advanced Gastric or Pancreatic Adenocarcinoma (Summary Last Modified 08/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: NCI-93-C-0164, NCI-NMOB-9301
Phase I Study of Raltitrexed in Children With Solid Tumors (Summary Last Modified 09/2001)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 12 and under
Sponsor: NCI
Protocol IDs: NCI-93-C-021O, NCI-T93-0109N, T93-0109
Phase I Study of Doxorubicin/Raltitrexed for Inoperable, Locally Advanced or Metastatic Gastric Cancer (Summary Last Modified 07/1999)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: CAN-NCIC-IND98, NCI-V96-1066, IND98
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065242, UPCC-T96-0063, JMC-T96-0063, NCI-T96-0063O, T96-0063, NCT00002902
Phase I Study of Raltitrexed (Tomudex) and Idoxuridine (IUDR) in Advanced Adult Solid Tumors (Summary Last Modified 04/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-960104, NCI-T96-0083, T96-0083
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065851, P30CA006927, FCCC-96116, NCI-T96-0113, T96-0113, NCT00003109
Raltitrexed in Treating Children With Refractory Acute Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-01839, 9779, U01CA097452, CDR0000066575, POG-9779, NCT00003528
Phase I Study of ICI D1694 in Adult Patients with Solid Tumors (Summary Last Modified 11/92)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-91-C-177D, NCI-MB-275, NCI-T91-0121N, T91-0121
Start Over